Factors reducing omalizumab response in severe asthma

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics.

Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab.

Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. Obesity (vs normal weight) was a determinant condition for exacerbations (OR:3.114[1.509-6.424], p = 0.002), for a disease partial/no control (OR:2.665[1.064-6.680], p = 0.036), for excessive SABA use (OR:4.448[1.837-10.768], p = 0.002) and for an unchanged/increased level of concomitant asthma medications. Furthermore, obesity also reduced the response in FEV1 (β = -6.981,p = 0.04), FVC (β = -11.689,p = 0.014) and ACT (β = -2.585, p = 0.027) and was associated with a higher FENO level (β = 49.045,p = 0.040). Having at least one comorbidity was a risk factor for exacerbations (OR:1.383[1.128-1.697], p = 0.008) and for an ACT <20 (OR:2.410[1.071-3.690], p = 0.008). Specifically, chronic heart disease was associated with both a lower ACT and FVC% whereas gastroesophageal reflux with a partial/no asthma control. Nasal polyps were a predisposing factor leading both to exacerbations and to the use of higher inhaled corticosteroids doses. Moreover, smoking habits, pollen or dog/cat dander co-sensitizations may negatively influence Omalizumab response.

Conclusion: Age, obesity, comorbidities, smoking habits, nasal polyps, allergic poly-sensitization might reduce Omalizumab effectiveness independently to other asthma-influencing factors.

Keywords: Age; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic response

full article

×
E' vietata la riproduzione anche parziale dei contenuti digitali (Audio, Video e Articoli)

Le indicazioni contenute in questo sito non intendono e non devono in alcun modo sostituire il rapporto diretto tra Medico (professionisti della salute) e Paziente/lettore. È pertanto sempre opportuno consultare sempre il proprio Medico curante e/o Specialista

Should omalizumab be used in severe asthma/COPD ov....
Should Inhaler Prescriptions Also Recommend Watchi....

Forse potrebbero interessarti anche questi articoli

Maggiori informazioni

Dott. Bruno Sposato svolge la propria attività presso l'Ospedale Misericordia di Grosseto, in via Senese 205.

Città:
Grosseto 58100 (Gr)
Indirizzo:
Via Senese 205
Telefono:
+39 0564 079414